# Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas

> **NCT01514201** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 66 (actual)

## Conditions studied

- Anaplastic Astrocytoma
- Brain Stem Glioma
- Childhood Mixed Glioma
- Fibrillary Astrocytoma
- Giant Cell Glioblastoma
- Glioblastoma
- Gliosarcoma
- Untreated Childhood Anaplastic Astrocytoma
- Untreated Childhood Brain Stem Glioma
- Untreated Childhood Fibrillary Astrocytoma
- Untreated Childhood Giant Cell Glioblastoma
- Untreated Childhood Glioblastoma
- Untreated Childhood Gliosarcoma

## Interventions

- **RADIATION:** 3-Dimensional Conformal Radiation Therapy
- **RADIATION:** Intensity-Modulated Radiation Therapy
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Temozolomide
- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT01514201
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-01
- **Primary completion:** 2018-03-28
- **Final completion:** 2018-03-28
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2019-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01514201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01514201, "Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01514201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*